Transradial pharmacology: do we need access relevant dosing to maximize outcome?
Ian C
IC
Gilchrist
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005263:Femoral Artery; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011677:Punctures; D017534:Radial Artery; D018570:Risk Assessment; D012307:Risk Factors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors